Dendreon Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Dendreon Corporation's estimated annual revenue is currently $75M per year.
- Dendreon Corporation's estimated revenue per employee is $118,297
- Dendreon Corporation's total funding is $35M.
Employee Data
- Dendreon Corporation has 634 Employees.
- Dendreon Corporation grew their employee count by -2% last year.
Dendreon Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Senior Assistant to VP IMF Operations | Reveal Email/Phone |
3 | SVP Legal and Compliance and General Counsel | Reveal Email/Phone |
4 | VP Sales, Marketing, Reimbursement, and Market Access | Reveal Email/Phone |
5 | VP, Commercial | Reveal Email/Phone |
6 | Head Marketing | Reveal Email/Phone |
7 | VP, Immunotherapy Manufacturing Facility Operations | Reveal Email/Phone |
8 | Vice president, Information Technology | Reveal Email/Phone |
9 | Head Quality @Dendreon Pharmaceuticals | Reveal Email/Phone |
10 | VP, Patient Operations | Reveal Email/Phone |
Dendreon Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Dendreon Corporation?
Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. Dendreon currently has three vaccine candidates in clinical trials -- Provenge, for the treatment of prostate cancer; Mylovenge(TM), for the treatment of multiple myeloma; and APC8024, for the treatment of breast, ovarian and colon cancers. Dendreon\'s product pipeline also includes monoclonal antibodies and a pathway to small molecules. Dendreon has established important alliances with industry leaders Genentech, Johnson & Johnson Pharmaceutical Research & Development and Kirin Brewery Co., Ltd.
keywords:N/A
$35M
Total Funding
634
Number of Employees
$75M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Dendreon Corporation News
... Inovio Pharmaceuticals, Advaxis, Johnson and Johnson, Dendreon Corporation, NewLink Genetics, GalaxoSmithKline, ImmunoGen.
Dendreon Corporation, Inovio Pharmaceuticals, ImmunoGen, NeoStem Oncology and Novartis. This Cancer Vaccine Market report covers important...
Dendreon Corporation, Inovio Pharmaceuticals, ImmunoGen, NeoStem Oncology and Novartis. The report provides a good overview of the key...
Dendreon is known for launching Provenge, a prostate cancer drug that was the first-ever immunotherapy treatment to get regulatory approval. Dendreon’s also known for filing for bankruptcy this past November, because of the drug’s poor performance – it was too costly at $93,000 and required too ...
Share Share on Facebook Share on Twitter LinkedIn Email Reprints [Updated: 1:15 pm PT] People at Seattle-based Dendreon (NASDAQ: DNDN) have been waiting for five weeks to find out how many employees would lose their jobs, after the company said it was falling short of its sales forecast for 201 ...